Deruxtecan

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) [1][2].

Product Specifications

CAS Number

[1599440-13-7]

Product Name Alternative

MC-GGFG-DXD

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Deruxtecan_analog.html

Purity

99.94

Solubility

DMSO : 73.33 mg/mL (ultrasonic)

Smiles

O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O

Molecular Formula

C52H56FN9O13

Molecular Weight

1034.05

Precautions

H302, H315, H319, H335

References & Citations

[1]NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.|[2]Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.